We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genes Identified that Cause Genomic Instability

By Biotechdaily staff writers
Posted on 22 Aug 2003
Cancer researchers working with a mouse model have found that the removal of the genes H2AX and P53 results in genetically unstable cells prone to give rise to lymphomas and solid tumors. More...


The H2AXT gene codes for a histone variant phosphorylated in chromatin surrounding DNA double-strand breaks. The P53 gene produces a molecular sentinel protein that suppresses proliferation of cells with damaged DNA.

Investigators at Harvard Medical School (Boston, MA, USA; www.harvard.edu) created a line of "double knockout” mice lacking both the H2AX and P53 genes. They found that these animals demonstrated a dramatically increased rate of tumors appearing beyond what would be seen with H2AX deficiency alone and far beyond p53 deficiency alone.

A second line of mice was developed that lacked only one of the two copies of the H2AX gene. "Both surprising and potentially very significant for human cancers was that p53-deficient mice with deletion of one of their two copies of the H2AX gene came down with cancer much earlier,” said senior author Dr. Fredrick W. Alt, professor of pediatrics and genetics at Harvard Medical School. "They showed a very broad spectrum of tumors that was somewhat different than p53-deficient animals missing both H2AX genes.”

The H2AX gene is located in a region of chromosome 11, which is known to be altered in many human tumors. The authors concluded their paper in the August 8, 2003, issue of Cell by saying that genes in that region will very likely prove to be major players in cancer-causing genomic instability.



Related Links:
Harvard Medical School

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.